News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EpiTherapeutics Receives Funding from Novo Nordisk A/S (NVO) and SEED Capital Denmark for Cancer Drug Development in the Field of Epigenetics


12/5/2008 8:50:44 AM

COPENHAGEN, Denmark--(BUSINESS WIRE)--Epitherapeutics Aps announced today the receipt of funding from two of the leading Danish life science investor groups, Novo A/S and SEED Capital Denmark to advance the discovery and development of new cancer treatments by leveraging breakthroughs in the field of Epigenetics.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES